Dan Werb




Dan Werb, PhD, is an epidemiologist and policy analyst with expertise in overdose, Human Immunodeficiency Virus (HIV), addictions, and drug policy. Dr. Werb is a Research Scientist at the Li Ka Shing Knowledge Institute (LKSKI) at St. Michael’s Hospital in Toronto. He is also an Assistant Professor in the Division of Infectious Diseases & Global Public Health at the University of California, San Diego. Dr.Werb is Director of the Centre on Drug Policy Evaluation, a recognized global leader in cutting edge policy research and communications. Dr. Werb has published dozens of studies on issues related to health policy and addictions, with a focus on preventing the transition of street youth into injection drug use, as well as on identifying the impact of policy and public health interventions on street-based drug-using populations.

Please note: Dr. Werb is not taking any summer students.


Recent Publications

  1. Salvalaggio, G, Brooks, H, Caine, V, Gagnon, M, Godley, J, Houston, S et al.. Flawed reports can harm: the case of supervised consumption services in Alberta. Can J Public Health. 2023;114 (6):928-933. doi: 10.17269/s41997-023-00825-x. PubMed PMID:37930628 PubMed Central PMC10661131.
  2. Bowles, J, Mansoor, M, Werb, D, Kerr, T, Bardwell, G. A qualitative assessment of tablet injectable opioid agonist therapy (TiOAT) in rural and smaller urban British Columbia, Canada: Motivations and initial impacts. J Subst Use Addict Treat. 2023;157 :209185. doi: 10.1016/j.josat.2023.209185. PubMed PMID:37865289 .
  3. Gaines, TL, Werb, D, Harris, O. Young, Black/African American, and Latino communities are left behind despite legislative efforts in California to reduce HIV/STI disparities. Front Reprod Health. 2023;5 :1179334. doi: 10.3389/frph.2023.1179334. PubMed PMID:37779638 PubMed Central PMC10538965.
  4. Karamouzian, M, Rafat, B, Kolla, G, Urbanoski, K, Atkinson, K, Bardwell, G et al.. Challenges of implementing safer supply programs in Canada during the COVID-19 pandemic: A qualitative analysis. Int J Drug Policy. 2023;120 :104157. doi: 10.1016/j.drugpo.2023.104157. PubMed PMID:37574645 .
  5. Guise, A, Harris, M, McCusker, M, McNeil, R, Werb, D. Stigma is stopping an evidence based response to drug overdose deaths in the UK. BMJ. 2023;382 :e074934. doi: 10.1136/bmj-2023-074934. PubMed PMID:37558236 .
  6. Algarin, AB, Werb, D, Shumskaya, N, Kurmanalieva, A, Blyum, A, Cepeda, J et al.. Financial Vulnerability and Its Association with HIV Transmission Risk Behaviors Among People Who Inject Drugs in Kyrgyzstan. AIDS Behav. 2023; :. doi: 10.1007/s10461-023-04129-6. PubMed PMID:37523049 .
  7. Gicquelais, RE, Astemborski, J, Werb, D, Kirk, GD, Mehta, SH, Genberg, BL et al.. Context and correlates of providing assistance with someone's first injection in the AIDS linked to the IntraVenous Experience cohort, Baltimore, MD. Drug Alcohol Depend. 2023;250 :110909. doi: 10.1016/j.drugalcdep.2023.110909. PubMed PMID:37517262 PubMed Central PMC10529208.
  8. Bouck, Z, Tricco, AC, Rosella, LC, Banack, HR, Fox, MP, Platt, RW et al.. First-line opioid agonist treatment as prevention against assisting others in initiating injection drug use: A longitudinal cohort study of people who inject drugs in Vancouver, Canada. Drug Alcohol Depend Rep. 2023;7 :100168. doi: 10.1016/j.dadr.2023.100168. PubMed PMID:37397436 PubMed Central PMC10311194.
  9. Nafeh, F, Werb, D, Karamouzian, M. The ups and downs of harm reduction in Afghanistan. Lancet Reg Health Southeast Asia. 2023;13 :100186. doi: 10.1016/j.lansea.2023.100186. PubMed PMID:37383551 PubMed Central PMC10306026.
  10. Ali, F, Russell, C, Greer, A, Bonn, M, Werb, D, Rehm, J et al.. "2.5 g, I could do that before noon": a qualitative study on people who use drugs' perspectives on the impacts of British Columbia's decriminalization of illegal drugs threshold limit. Subst Abuse Treat Prev Policy. 2023;18 (1):32. doi: 10.1186/s13011-023-00547-w. PubMed PMID:37322496 PubMed Central PMC10268332.
Search PubMed

Affiliations & Other Activities

  • Assistant Professor, Division of Global Public Health, University of California San Diego Director, International Centre for Science in Drug Policy